Amyloid imaging in vivo: implications for Alzheimer's disease management.


β-Amyloid (Aβ) modification therapies for Alzheimer's disease are being developed that target Aβ production, aggregation and/or degradation. Some of these medications are already in Phase III studies. Therefore, it will be most relevant to be able to quantify the neurobiological target of such therapies directly in vivo in the brain. This could allow a… (More)
DOI: 10.1517/17530059.1.3.337